Today we announced that the first patient has been dosed in Orum’s Phase 1 trial of ORM-1153, a CD123-GSPT1 degrader-antibody conjugate, in relapsed or refractory AML and other CD123-expressing blood cancers. Read the release for more: orumrx.com/news/orum-therape…

The FDA has cleared Orum’s IND for ORM-1153, advancing its TPD²® approach into CD123-expressing hematologic malignancies. Phase 1 testing of the novel CD123-GSPT1 degrader-antibody conjugate is planned by the end of 2026. Release: orumrx.com/news/orum-therape…

Orum Therapeutics Presents New Preclinical Data at #AACR26 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in Acute Myeloid Leukemia and the Potential for Improved Efficacy and Tolerability orumrx.com/news/orum-present…

Orum has appointed Dr. Maria Koehler and Geoff Meyerson to its BOD, adding clinical development, translational oncology, company-building, and strategic transaction expertise as we advance our next wave of degrader-antibody conjugate programs. orumrx.com/news/orum-therape…

Orum Therapeutics will present new preclinical data on ORM-1153, a CD123-targeting degrader antibody conjugate, at #AACR26. Two posters will be presented on April 20 from 9am-12pm PDT. Read the release for more details: orumrx.com/news/hiev0874tmys…

Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs Read the press release for more: bit.ly/49mSUyr

Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases Read the press release for more: bit.ly/4qdKkZk

Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting See the press release for details: bit.ly/47AS0x5 #ASH25 #DegraderAntibodyConjugates #AML #BloodCancers #AcuteMyeloidLeukemia

𝗔𝗿𝗲 𝗗𝗔𝗖𝘀 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗔𝗗𝗖𝘀? In @DDWJournal, Orum Founder and CEO SJ Lee discusses how degrader-antibody conjugates unite antibody precision with catalytic protein degradation to reach targets once considered “undruggable.” ddw-online.com/are-dacs-the-…

Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s #DegraderAntibodyConjugate Payload Platforms and Expand TPD²® Therapeutic Applications Read the release: bit.ly/4qg143e #TargetedProteinDegradation #ADCs #AntibodyDrugConjugates

We’re growing! Orum Therapeutics is hiring across several roles as we advance our mission to develop new medicines for patients. Hear from our team & explore openings: orumtherapeutics.bamboohr.co… #Hiring #BiotechCareers #JoinOurTeam #LifeAtOrum

Orum CEO SJ Lee joins 𝙏𝙝𝙚 𝘽𝙞𝙤𝘾𝙚𝙣𝙩𝙪𝙧𝙮 𝙎𝙝𝙤𝙬 to talk about building a global biotech in Korea, the promise of DACs, and why degraders may succeed where traditional #ADCs fall short. More at @BioCentury: bit.ly/4kDa13e #DegraderAntibodyConjugates

Orum’s Founder & CEO SJ Lee joined leaders at @UBS Asian Investment Conference (AIC) 2025, where he discussed Korea’s biotech momentum and Orum is paving the way in #TargetedProteinDegradation as a first mover with its novel #DegraderAntibodyConjugates. #UBSAIC

Orum’s Founder and CEO SJ Lee shares his perspective on why hybrid biologics — including degrader–antibody conjugates (DACs) — are key to driving therapeutic innovation Read on @pharmasalmanac: bit.ly/4daXGR1 #DegraderAntibodyConjugates #ADCs #ProteinDegradation

Orum’s Founder & CEO SJ Lee speak on a panel at @UBS Asian Investment Conference (AIC) 2025 discussing Korea’s biotech sector and Orum’s differentiated approach to #TargetedProteinDegradation with novel #DegraderAntibodyConjugates. bit.ly/43gWMhf #UBSAIC